News tagged with avastin
Avastin disappoints against ovarian cancer
Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...
Cancer
Dec 28, 2011 |
4.3 / 5 (4) |
1
Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.
Cancer
Apr 19, 2013 |
5 / 5 (2) |
0
|
'Microbeads' may boost survival in advanced colon cancer patients
(HealthDay News) —For advanced colon cancer patients who have developed liver tumors, so-called "radioactive beads" implanted near these tumors may extend survival nearly a year longer than among patients ...
Cancer
Jan 21, 2013 |
not rated yet |
0
|
Avastin won't extend breast cancer survival: study
(HealthDay)—The drug Avastin (bevacizumab), when added to chemotherapy, does not improve disease-free survival in patients with triple-negative breast cancer any better than chemo alone, new research finds.
Medications
Dec 07, 2012 |
not rated yet |
0
|
Avastin has similar effect to Lucentis in treating wet age-related macular degeneration
The one year results from a study into whether two drug treatments (Lucentis and Avastin), are equally effective in treating neovascular or wet age-related macular degeneration (wet AMD), have been reported today at an international ...
Ophthalmology
May 07, 2012 |
not rated yet |
0
|
Avastin no benefit to older lung cancer patients: study
(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer ...
Cancer
Apr 17, 2012 |
not rated yet |
0
|
Studies: Avastin may fight early breast cancers
Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers found.
Cancer
Jan 25, 2012 |
5 / 5 (2) |
0
Avastin, Sutent increase breast cancer stem cells, study shows
Cancer treatments designed to block the growth of blood vessels were found to increase the number of cancer stem cells in breast tumors in mice, suggesting a possible explanation for why these drugs don't ...
Cancer
Jan 25, 2012 |
5 / 5 (1) |
1
|
Targeted therapy extends progression-free survival of patients with advanced ovarian cancer
Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic ...
Cancer
Dec 28, 2011 |
not rated yet |
0
|
US revokes Roche's Avastin for breast cancer
US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."
Medications
Nov 18, 2011 |
not rated yet |
0
Scientists find link between immune system suppression, blood vessel formation in tumors
Targeted therapies that are designed to suppress the formation of new blood vessels in tumors, such as Avastin (bevacizumab), have slowed cancer growth in some patients. However, they have not produced the dramatic responses ...
Cancer
Jul 13, 2011 |
not rated yet |
0
|
Study finds Avastin and Lucentis are equally effective in treating AMD
Researchers are reporting results from the first year of a two-year clinical trial that Avastin, a drug approved to treat some cancers and that is commonly used off-label to treat age-related macular degeneration (AMD), is ...
Diseases, Conditions, Syndromes
Apr 28, 2011 |
not rated yet |
0
|
Researchers follow a path to a potential therapy for NF2, a rare tumor disorder
The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2 (NF2), an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, ...
Cancer
Apr 15, 2011 |
not rated yet |
0
|
FDA device will screen for fake medicines overseas
U.S. health officials are making a high-tech screening device available to African authorities to help spot counterfeit malaria pills in hopes that the technology may eventually be used to combat the fake drug trade worldwide.
Medications
Apr 24, 2013 |
not rated yet |
0
Clinical trials helped one woman's fight against cancer
(HealthDay)—Monica Barlow, a 35-year-old from Maryland, was training for a half-marathon when she noticed she couldn't shake a bad cough and ongoing fatigue. After a couple of rounds of antibiotics from ...
Cancer
Apr 18, 2013 |
not rated yet |
0
Bevacizumab
Bevacizumab (trade name Avastin, Genentech/Roche) is a monoclonal antibody that recognises all vascular endothelial growth factor (VEGF) isoforms. It is used in the treatment of cancer, where it inhibits tumor growth by blocking the formation of new blood vessels (angiogenesis). Bevacizumab was the first clinically available angiogenesis inhibitor in the United States.
Bevacizumab is currently approved by the U.S. Food and Drug Administration (FDA) for cancers that are metastatic (have spread to other parts of the body). It received its first approval in 2004 was for combination use with standard chemotherapy for metastatic colon cancer and non-small cell lung cancer. In 2008, it was approved by the FDA for use in metastatic breast cancer, a decision that generated some controversy as it went against the recommendation of its advisory panel, who objected because it only slowed tumor growth but failed to extend survival.
Clinical studies are underway in non-metastatic breast cancer, renal cell carcinoma, glioblastoma multiforme, ovarian cancer, castrate-resistant (formally called hormone refractory) prostate cancer, non-metastatic unresectable liver cancer and metastatic or unresectable locally advanced pancreatic cancer. A study released in April 2009 found that bevacizumab is not effective at preventing recurrences of non-metastatic colon cancer following surgery. In May 2009, it received FDA approval for treatment of reoccurring Glioblastoma Multiforme, while treatment for initial growth is still in phase III clinical trial.
For more information about Bevacizumab, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
